Eisai's LEQEMBI® Included in China's Innovative Drug List, Enhancing Alzheimer's Treatment Access
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 day ago0mins
- Inclusion in Drug List: LEQEMBI® has been added to China's Commercial Insurance Innovative Drug List by the NHSA, marking a significant step in improving access to early Alzheimer's Disease treatment for approximately 17 million patients.
- Policy Support: This list aims to bridge the coverage gap between the National Reimbursement Drug List and innovative medicines, facilitating agreements between commercial insurers and pharmaceutical companies to promote market access for innovative drugs.
- Market Outlook: Launched in China in June 2024, LEQEMBI® is expected to see increased demand as the aging population leads to a rise in Alzheimer's Disease cases, enhancing its market potential.
- Collaborative Model: Eisai and Biogen co-promote LEQEMBI®, with Eisai leading global development and regulatory efforts, ensuring effective distribution and information provision in China, thereby strengthening their competitive position in the Alzheimer's market.
BIIB.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 184.00 USD with a low forecast of 149.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
12 Buy
10 Hold
0 Sell
Moderate Buy
Current: 175.840
Low
149.00
Averages
184.00
High
250.00
Current: 175.840
Low
149.00
Averages
184.00
High
250.00
HSBC
Hold -> Reduce
downgrade
$144 -> $143
2025-12-10
New
Reason
HSBC
Price Target
$144 -> $143
2025-12-10
New
downgrade
Hold -> Reduce
Reason
HSBC downgraded Biogen to Reduce from Hold with a price target of $143, down from $144. The company's "ailing" multiple sclerosis franchise is outweighing its growth elsewhere, the analyst tells investors in a research note. The firm expects margin pressure from lower royalties and says Biogen's 50% share re-rating is overdone. The company has limited near-term earnings improvement potential and risk to its long-term earnings power, contends HSBC.
Piper Sandler
Neutral
maintain
$118 -> $157
2025-11-21
Reason
Piper Sandler
Price Target
$118 -> $157
2025-11-21
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Biogen to $157 from $118 and keeps a Neutral rating on the shares. The firm notes that Biogen shares have certainly participated in the broader rally of the biopharma space in recent months, with the stock up about 35% since the beginning of Q3 2025.
Stifel
Hold -> Buy
upgrade
$144 -> $202
2025-11-06
Reason
Stifel
Price Target
$144 -> $202
2025-11-06
upgrade
Hold -> Buy
Reason
Stifel upgraded Biogen to Buy from Hold with a price target of $202, up from $144, following the Q3 report. The firm believes the stock's risk/reward is shifting favorably with clinical catalysts ahead. The upgrade is not a call on the base business, as Biogen's Q3 results were mixed and Q4 "will be just okay," the analyst tells investors in a research note. However, Stifel believes Biogen shares can trade higher in the next 12 months due to a "narrative shift" in Alzheimer's. This will be supported by potential success of Eli Lily's TRAILBLAZER-ALZ 3 trial, which could fundamentally change the way doctors and investors think about amyloid beta antibodies, the analyst tells investors in a research note. Biogen offers "unique optionality even if clinical catalysts still have risks," contends the firm.
Bernstein
Bernstein
Market Perform
maintain
$155 -> $157
2025-11-03
Reason
Bernstein
Bernstein
Price Target
$155 -> $157
2025-11-03
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Biogen to $157 from $155 and keeps a Market Perform rating on the shares following quarterly results. The performance of multiple sclerosis Franchise and to a lesser extent Anti-CD20 drove the revenue beat, outpacing consensus by 14% and 10%, respectively, the firm notes. Leqembi's miss took away the shine from this beat, and while this can be partly explained by channel dynamics, the broader competitive environment looks increasingly challenging, Bernstein adds.
See All Ratings
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key differences between subcutaneous and intravenous LEQEMBI formulations?
How does LEQEMBI delay Alzheimer's progression by targeting Aβ protofibrils?
How might the approval of subcutaneous LEQEMBI impact Biogen's market share globally?
What could be the long-term effects of LEQEMBI on Alzheimer's treatment strategies?